Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/186888
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Youssef, Lina | - |
dc.contributor.author | Crovetto, Francesca | - |
dc.contributor.author | Crispi Brillas, Fátima | - |
dc.contributor.author | Gratacós Solsona, Eduard | - |
dc.contributor.author | Palomo, Marta | - |
dc.contributor.author | Ramos, Alex | - |
dc.contributor.author | Torramade Moix, Sergi | - |
dc.contributor.author | Moreno Castaño, Ana Belen | - |
dc.contributor.author | Martinez Sanchez, Julia | - |
dc.contributor.author | Bonastre, Laura | - |
dc.contributor.author | Pino, Marc | - |
dc.contributor.author | Gomez Ramirez, Pilar | - |
dc.contributor.author | Martin, Lidia | - |
dc.contributor.author | Garcia Mateos, Estefania | - |
dc.contributor.author | Sanchez, Pablo | - |
dc.contributor.author | Fernandez, Sara | - |
dc.contributor.author | Escolar Albaladejo, Ginés | - |
dc.contributor.author | Carreras, Enric | - |
dc.contributor.author | Castro, Pedro | - |
dc.contributor.author | Diaz Ricart, M. Isabel | - |
dc.date.accessioned | 2022-06-21T11:19:53Z | - |
dc.date.available | 2022-06-21T11:19:53Z | - |
dc.date.issued | 2022-03-26 | - |
dc.identifier.issn | 1097-6868 | - |
dc.identifier.uri | http://hdl.handle.net/2445/186888 | - |
dc.description.abstract | Background: COVID-19 presents a spectrum of signs and symptoms in pregnant women that might resemble preeclampsia. Differentiation between severe COVID-19 and preeclampsia is difficult in some cases. Objective: To study biomarkers of endothelial damage, coagulation, innate immune response, and angiogenesis in preeclampsia and COVID-19 in pregnancy in addition to in vitro alterations in endothelial cells exposed to sera from pregnant women with preeclampsia and COVID-19. Study design: Plasma and sera samples were obtained from pregnant women with COVID-19 infection classified into mild (n=10) or severe (n=9) and from women with normotensive pregnancies as controls (n=10) and patients with preeclampsia (n=13). A panel of plasmatic biomarkers was assessed, including vascular cell adhesion molecule-1, soluble tumor necrosis factor-receptor I, heparan sulfate, von Willebrand factor antigen (activity and multimeric pattern), α2-antiplasmin, C5b9, neutrophil extracellular traps, placental growth factor, soluble fms-like tyrosine kinase-1, and angiopoietin 2. In addition, microvascular endothelial cells were exposed to patients' sera, and changes in the cell expression of intercellular adhesion molecule 1 on cell membranes and von Willebrand factor release to the extracellular matrix were evaluated through immunofluorescence. Changes in inflammation cell signaling pathways were also assessed by of p38 mitogen-activated protein kinase phosphorylation. Statistical analysis included univariate and multivariate methods. Results: Biomarker profiles of patients with mild COVID-19 were similar to those of controls. Both preeclampsia and severe COVID-19 showed significant alterations in most circulating biomarkers with distinctive profiles. Whereas severe COVID-19 exhibited higher concentrations of vascular cell adhesion molecule-1, soluble tumor necrosis factor-α receptor I, heparan sulfate, von Willebrand factor antigen, and neutrophil extracellular traps, with a significant reduction of placental growth factor compared with controls, preeclampsia presented a marked increase in vascular cell adhesion molecule-1 and soluble tumor necrosis factor-α receptor I (significantly increased compared with controls and patients with severe COVID-19), with a striking reduction in von Willebrand factor antigen, von Willebrand factor activity, and α2-antiplasmin. As expected, reduced placental growth factor, increased soluble fms-like tyrosine kinase-1 and angiopoietin 2, and a very high soluble fms-like tyrosine kinase-1 to placental growth factor ratio were also observed in preeclampsia. In addition, a significant increase in C5b9 and neutrophil extracellular traps was also detected in preeclampsia compared with controls. Principal component analysis demonstrated a clear separation between patients with preeclampsia and the other groups (first and second components explained 42.2% and 13.5% of the variance), mainly differentiated by variables related to von Willebrand factor, soluble tumor necrosis factor-receptor I, heparan sulfate, and soluble fms-like tyrosine kinase-1. Von Willebrand factor multimeric analysis revealed the absence of von Willebrand factor high-molecular-weight multimers in preeclampsia (similar profile to von Willebrand disease type 2A), whereas in healthy pregnancies and COVID-19 patients, von Willebrand factor multimeric pattern was normal. Sera from both preeclampsia and severe COVID-19 patients induced an overexpression of intercellular adhesion molecule 1 and von Willebrand factor in endothelial cells in culture compared with controls. However, the effect of preeclampsia was less pronounced than the that of severe COVID-19. Immunoblots of lysates from endothelial cells exposed to mild and severe COVID-19 and preeclampsia sera showed an increase in p38 mitogen-activated protein kinase phosphorylation. Patients with severe COVID-19 and preeclampsia were statistically different from controls, suggesting that both severe COVID-19 and preeclampsia sera can activate inflammatory signaling pathways. Conclusion: Although similar in in vitro endothelial dysfunction, preeclampsia and severe COVID-19 exhibit distinctive profiles of circulating biomarkers related to endothelial damage, coagulopathy, and angiogenic imbalance that could aid in the differential diagnosis of these entities. | ca |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | ca |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.ajog.2022.03.048 | - |
dc.relation.ispartof | American Journal of Obstetrics and Gynecology, 2022 | - |
dc.relation.uri | https://doi.org/10.1016/j.ajog.2022.03.048 | - |
dc.rights | cc by-nc-nd Elsevier, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (BCNatal Fetal Medicine Research Center) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Preeclàmpsia | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Preeclampsia | - |
dc.title | Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy. | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
dc.identifier.pmid | 35351411 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (BCNatal Fetal Medicine Research Center) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
23_Palomo M_2022.pdf | 6.71 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License